Distribution of Common and Rare Genetic Markers of Second-Line-Injectable-Drug Resistance in Mycobacterium tuberculosis Revealed by a Genome-Wide Association Study-Reference-Cited by-同舟云学术

Distribution of Common and Rare Genetic Markers of Second-Line-Injectable-Drug Resistance in Mycobacterium tuberculosis Revealed by a Genome-Wide Association Study

Published:2022-06-21 Issue:6 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Conkle-Gutierrez Derek¹^ORCID,Kim Calvin¹,Ramirez-Busby Sarah M.¹,Modlin Samuel J.¹^ORCID,Mansjö Mikael²,Werngren Jim²,Rigouts Leen³⁴,Hoffner Sven E.¹⁵,Valafar Faramarz¹^ORCID

Affiliation:

1. Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence (LPCDRP), Biomedical Informatics Research Center, Division of Epidemiology, School of Public Health, San Diego State University, San Diego, California, USA

2. Department of Microbiology, Public Health Agency of Sweden, Solna, Sweden

3. Department of Biomedical Sciences, Antwerp University (UA), Antwerp, Belgium

4. Mycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine (ITM), Antwerp, Belgium

5. Department of Global Public Health, Karolinska Institute, Stockholm, Sweden

Abstract

Point mutations in the rrs gene and the eis promoter are known to confer resistance to the second-line injectable drugs (SLIDs) amikacin (AMK), capreomycin (CAP), and kanamycin (KAN). While mutations in these canonical genes confer the majority of SLID resistance, alternative mechanisms of resistance are not uncommon and threaten effective treatment decisions when using conventional molecular diagnostics.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.02075-21

Reference64 articles.

1. World Health Organization. 2021. Global tuberculosis report 2021. World Health Organization, Geneva, Switzerland.

2. World Health Organization. 2019. Global tuberculosis report 2019. Document number WHO/CDS/TB/2019.15. World Health Organization, Geneva, Switzerland.

3. World Health Organization. 2014. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Document number WHO/HTM/TB/2014.11. World Health Organization, Geneva, Switzerland.

4. Drug Resistance Mechanisms in Mycobacterium tuberculosis

5. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-resistant Mycobacterium tuberculosis among Nepalese patients at a tuberculosis referral center;PLOS ONE;2024-05-06

2. Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases;Microbiology Spectrum;2024-05-02

3. Comparison of the MeltPro TB assay and whole-genome sequencing assay for rapid molecular diagnosis of drug resistant tuberculosis in guangdong province;Diagnostic Microbiology and Infectious Disease;2024-02

4. Genome-Wide Association Studies (GWAS) Approaches for the Detection of Genetic Variants Associated with Antibiotic Resistance: A Systematic Review;Microorganisms;2023-11-27